Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hibiscus 2: etavopivat in sickle cell disease
PACTR202406801520269Phase 3Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of etavopivat in sickle cell disease (SCD), sponsored by Novo Nordisk. Primary endpoints: Number of adjudicated vaso-occlusive crisis events with a medical contact, Time to onset of first adjudicated vaso-occlusive crisis and 2 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202406801520269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202406801520269.